TY - JOUR A2 - Brinton, Eliot AU - Forslund, Tomas AU - Raaschou, Pauline AU - Hjemdahl, Paul AU - Krakau, Ingvar AU - Wettermark, Bj√∂rn PY - 2011 DA - 2011/06/06 TI - Usage, Risk, and Benefit of Weight-Loss Drugs in Primary Care SP - 459263 VL - 2011 AB - Purpose. To investigate the use of the weight-loss drugs rimonabant, sibutramine, and orlistat in primary care and to characterize the patients receiving the drugs. Methods. In this retrospective, descriptive study, 300 randomly selected patients having started weight-loss drug treatment at 15 primary care centres were investigated using the patient's medical records and their complete drug purchase data. Results. Even though 48% of the patients specifically demanded drug treatment, 77% continued treatment less than one year. 28% of rimonabant patients and 32% of sibutramine patients had a history of depression or antidepressant treatment. 41% of sibutramine patients had a history of hypertension and/or cardiovascular disease. 36% had no documented weight after treatment initiation. Conclusions. These results suggest that weight-loss drug treatment was often initiated upon patient request but was of limited clinical benefit as it was managed in a large portion of Swedish primary carecenters. SN - 2090-0708 UR - https://doi.org/10.1155/2011/459263 DO - 10.1155/2011/459263 JF - Journal of Obesity PB - Hindawi Publishing Corporation KW - ER -